Pipertaz Sandoz Side effects

What is the dose of your medication?
sponsored

What are the possible side effects of Pipertaz Sandoz?

Get emergency medical help if you have signs of an allergic reaction to Pipertaz Sandoz: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

Common Pipertaz Sandoz side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Side effects of Pipertaz Sandoz in details

sponsored

Adverse drug reactions reported with Pipertaz Sandoz are similar to those reported with Piperacillin (Pipertaz Sandoz) alone and generally are transient and mild to moderate in severity. Adverse events have been reported in about ≤10% of patients receiving parenteral Pipertaz Sandoz and have been severe enough to require discontinuance in ≤3% of patients.

The most common frequent adverse effects reported with Pipertaz Sandoz are gastrointestinal (GI) effects, headache and hypersensitivity reactions.

Hypersensitivity Reactions: Rash, pruritus and fever have been reported in up to 4% of patients receiving Pipertaz Sandoz. Rare reports of bronchospasm have also been reported.

Gastrointestinal Effects: Diarrhea, nausea, constipation have been reported in up to 11% of patients receiving Pipertaz Sandoz. Vomiting, dyspepsia, stool changes and abdominal pain can occur in up to 3%, while melena, flatulence, hemorrhage, gastritis, hiccups and ulcerative stomatitis are reported in ≤1% of patients.

Clostridium difficile-associated diarrhea and colitis or antibiotic-associated pseudomembranous colitis have been reported in at least 1 patient receiving Pipertaz Sandoz. Colitis may occur during or following discontinuance of anti-infective therapy and may range in severity from mild to life-threatening.

Hematologic Effects: Transient leukopenia, neutropenia and thrombocytopenia have been reported in patients receiving Pipertaz Sandoz for a prolonged period of time (eg, after ≥21 days) and generally were reversible, systemic symptoms (eg, fever, rigors and chills) may also occur in some patients. Epistaxis and purpura have been reported in ≤1% patients.

Hepatic Effects: Transient increases in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase and bilirubin can occur.

Renal Effects: Increases in serum concentrations of creatinine and blood urea nitrogen (BUN) may be observed. Urinary retention, dysuria, oliguria, hematuria and incontinence have been reported in ≤1% and proteinuria, pyuria, leukorrhea and vaginitis can also occur.

Effect on the Central Nervous System: Headache and insomnia have been reported in up to 7-8%, while agitation, dizziness and anxiety have been reported in ≤2% patients. Tremors, seizures, vertigo, confusion, hallucination, malaise and depression have been reported in ≤1% of patients receiving Pipertaz Sandoz. Neuromuscular excitability or seizures could occur in higher than recommended doses are given IV, especially in patients with kidney failure.

Local Reactions: Adverse reactions at the injection site have been reported in ≤1% of patients. Adverse local reactions include phlebitis, pain, inflammation, thrombophlebitis and edema.

Other Adverse Effects: Hypertension, chest pain, edema, moniliasis, rhinitis, dyspnea, hypotension, ileus, syncope and rigors have been reported in ≤2% of patients. Tachycardia, bradycardia, heart failure and myocardial infarction have been reported in at most 1%.

What is the most important information I should know about Pipertaz Sandoz?

Pipertaz Sandoz contraindications

sponsored

Pipertaz Sandoz for injection is contraindicated in patients with a history of allergic reactions to any of the penicillins, cephalosporins, or β-lactamase inhibitors.

References

  1. European Chemicals Agency - ECHA. "4-Thia-1-azabicyclo [3.2.0] heptane-2-carboxylic acid,6-[[[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino] phenylacetyl]amino]-3,3-dimethyl-7-oxo-,monohydrate, [2S-[2alpha, 5alpha, 6beta(S*)]]: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
  2. European Chemicals Agency - ECHA. "4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, sodium salt (1:1), (2S,3S,5R)-: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
  3. NCIt. "Tazobactam: NCI Thesaurus (NCIt) provides reference terminology for many systems. It covers vocabulary for clinical care, translational and basic research, and public information and administrative activities.". https://ncit.nci.nih.gov/ncitbrowser... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Pipertaz Sandoz are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Pipertaz Sandoz. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported side effects

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 14 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2024 ndrugs.com All Rights Reserved